Advertisement

Imaging in Bladder Cancer: Can We Do Better?

  • Giovanni Barchetti
  • Vincenzo Salvo
  • Davide Fierro
  • Maurizio Del Monte
  • Isabella Ceravolo
  • V. Panebianco
Chapter

Abstract

Imaging studies are required for disease staging in muscle-invasive bladder cancer in order to evaluate the extent of local tumour invasion, the presence of tumour spread to lymph nodes and the presence of tumour spread to upper urinary tract and/or to other distant organs. Magnetic resonance (MRI) as has a higher accuracy compared to computed tomography CT for primary tumour staging thanks to its superior soft tissue contrast; however, CT remains the most commonly used imaging modality, due to its shorter acquisition time and lower susceptibility to variations related to patients’ characteristics. As regards to primary tumour detection, virtual cystoscopy has been developed with promising results. To determine the lymph node status of patients with muscle-invasive bladder cancer FDG PET/CT has been tested: it seems to provide advantages over CT and MRI in lymph node assessment, even if more evidences are required. Finally, but perhaps more importantly, MRI is currently deemed to be able to differentiate T1 from T2 tumors. As this step is the most important and often the most time- and resources-consuming, if MRI is demonstrated to be reliable in such differentiation, the first steps of the diagnostic process of bladder cancer may be changed.

Keywords

MRI CT FDG PET Diagnosis Imaging 

References

  1. 1.
    Kundra V, et al. Imaging in oncology from the university of Texas M.D. Anderson Cancer Center. Imaging in the diagnosis, staging and follow-up of cancer of the urinary bladder. Am J Roentgenol. 2003;180:1045.CrossRefGoogle Scholar
  2. 2.
    Barentsz JO, et al. Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT. Eur Radiol. 1996;6:129.CrossRefPubMedGoogle Scholar
  3. 3.
    Leyendecker JR, Barnes CE, Zagoria RJ. MR urography: techniques and clinical applications. Radiographics. 2008;28:23–46.CrossRefPubMedGoogle Scholar
  4. 4.
    Portnoy O, et al. Optimization of 64-MDCT urography: effect of dual-phase imaging with furosemide on collecting system opacification and radiation dose. Am J Roentgenol. 2011;197:W882–6.CrossRefGoogle Scholar
  5. 5.
    Yousem DM, Gatewood OM, Goldman SM, Marshall FF. Synchronous and metachronous transitional cell carcinoma of the urinary tract: prevalence, incidence, and radiographic detection. Radiology. 1988;167:613–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Yu RJ, Stein JP, Cai J, Miranda G, Groshen S, Skinner DG. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol. 2006;176:493–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Panebianco V, Sciarra A, Di Martino M, et al. Bladder carcinoma: MDCT cystography and virtual cystoscopy. Abdom Imaging. 2010;35:257–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Caterino M, Giunta S, Finocchi V, et al. Primary cancer of the urinary bladder: CT evaluation of the T parameter with different techniques. Abdom Imaging. 2001;26:433–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY, Kao CH. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2012;81(9):2411–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Panebianco V, Barchetti F, de Haas RJ, Pearson RA, Kennish SJ. Improving staging in bladder cancer: the increasing role of multiparametric magnetic resonance imaging. Eur Urol Focus. 2016;2(2):113–21.CrossRefPubMedGoogle Scholar
  11. 11.
    Panebianco V, De Berardinis E, Barchetti G, Simone G, Leonardo C, Grompone MD, Del Monte M, Carano D, Gallucci M, Catto J, Catalano C. An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol. 2017;27(9):3759–66.  https://doi.org/10.1007/s00330-017-4758-3. [Epub ahead of print].CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Giovanni Barchetti
    • 1
  • Vincenzo Salvo
    • 1
  • Davide Fierro
    • 1
  • Maurizio Del Monte
    • 1
  • Isabella Ceravolo
    • 1
  • V. Panebianco
    • 1
  1. 1.Department of Radiological Sciences, Oncology and PathologySapienza University/Policinico Umberto I of RomeRomeItaly

Personalised recommendations